10/532341

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: . Kurt Frimann BERG)	Art Unit:
Marc Framam Band)	Examiner:
Serial No.: 10/532,341)	Washington, D.C.
Filed: September 19, 2003)	December 16, 2005
For: PHARMACEUTICAL COMPOSITION COMPRISING FLAVONOIDS AND	(IS))	Docket No.: BERG3

INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner of Patents and Trademarks Washington, D.C. 20231

Sir:

This Information Disclosure Statement is submitted in accordance with 37 C.F.R. 1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

- 1. This IDS should be considered, in accordance with 37 C.F.R. 1.97, as it is filed:
- [] A. within three months of the filing date of the above-identified national application or within three months of the entry into the national stage of the above-identified international application. See 37 CFR 1.97(b).
- [X] B. before the mailing date of a first office action on the merits. See 37 CFR 1.97(b).
- [] C. after (A) and (B) above, but before final rejection or allowance, and Applicants have made the necessary certification (box "i" below) or paid the necessary fee (box "i"

The second secon

below). See 37 CFR 1.97(c).

- [] i. Counsel certifies that, upon information and belief, each item of information listed herein was either (a) cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS or (b) was not cited in a communication from a foreign patent office in a counterpart foreign application and was not known to any individual designated in 1.56(c) more than three months prior to the filing of this IDS.
- [] ii. A check for the fee set forth in 1.17(p), presently believed to be \$180, is enclosed (check no. _____).
- D. after (A), (B) and (C) above, but before payment of the issue fee. Applicant petitions under 37 C.F.R. 1.97(d) for consideration of this IDS. A check for the fee set forth in 1.17(i)(1), presently believed to be \$130 is enclosed). Counsel certifies (check no. that, information and belief, each item of information listed herein was either (i) cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS or (ii) was not cited in a communication from a foreign patent office in a counterpart foreign application and was not known to any individual designated in 1.56(c) more than three months prior to the filing of this IDS.
- [] E. As a submission in accordance with the transitional procedure for limited examination after final rejection pursuant to 37 CFR §1.129(a). Pursuant to MPEP §706.07(g), page 700-46, col. 2 (February 2000), this IDS is treated as if filed with a period set forth in 37 CFR §1.97(b)

T.Z.

and considered without the petition and petition fee required by 1.97(d).

- 2. In accordance with 37 C.F.R. 1.98, this IDS includes a list (e.g., form PTO-1449) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. A copy of each document is attached, except as explained below.
- [X] While an IDS filed under \$1.97 must contain a "list of all patents, publications or other information submitted for consideration by the Office", see \$1.98(a) (1), the only requirement for the list is that it provide the information set forth in \$1.98(b). There is no requirement that a form PTO-1449 be used (MPEP \$609 merely says that use of this form is "encouraged"). Counsel has used a list provided to him by Applicants, and not transferred the information to a PTO-1449, to avoid the risk of any inadvertent error in transferring the information.
- [] A. Documents _____ are deemed substantially cumulative to documents _____, and, in accordance with 1.98(c), only a copy of each of the latter documents is enclosed.
- [] B. Certain documents were previously cited by or submitted to the Office in the following prior application(s), which are relied upon under 35 U.S.C. 120:

[insert serial number/filing date]

Applicants identify these documents by attaching hereto copies of the form PTO-892s and PTO-1449s from the files of the prior applications or a fresh PTO-1449 listing these documents, and request that they be considered and made of record in accordance

with 1.98(d). Per 37 CFR 1.98(d), copies of these documents need not be filed in this application. If copies of any of these documents cannot be found in the files of the prior applications, the Examiner is requested to so notify counsel before taking action in this case, so replacement copies can be submitted. While an IDS filed under \$1.97 must contain a "list of all patents, publications or other information submitted for consideration by the Office", see \$1.98(a) (1), the only requirement for the list is that it provide the information set forth in \$1.98(b). There is no requirement that a form PTO-1449 be used (MPEP \$609 merely says that use of this form is "encouraged") and no prohibition on submitting a copy of a form PTO-1449 or form PTO-892 from a prior case. Indeed, the re-use of such forms is desirable as it avoids error in transferring the information, and evidences that the reference was considered in a prior application. A previously accepted PTO-1449, or an examiner-prepared PTO-892, necessarily complies with §1.98(b).

[X] 3. Documents \underline{AT} , \underline{AV} , \underline{AW} , and \underline{AX} are not in the English language. In accordance with 1.98(c), Applicants state:

- [] documents _____ already contain an English language abstract, summary or claim set.
- [X] a publicly available abstract is attached to each of documents AV, AW, and AX, and the source of each abstract is indicated thereon.
- [] documents _____ are patents or published patent applications for which counterpart English language patents or patent applications exist, and are enclosed, as follows:

Foreign Lang. Doc.# English Lang. Doc.# [insert]

ુ.√.

[] applicants have prepared an English translation of

- at least the pertinent portions of documents _____, and copies are attached.
- [X] A concise explanation of the relevance of documents <u>AT</u> is found in the attached search report from the <u>European</u> Patent Office (see reply to Comment 68 in the preamble to the final rules; 1135 OG 13 at 20).
- [] A concise explanation of the relevance of documents _____ is set forth as follows:

 [Insert concise explanation of relevance]
- 4. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).
- 5. Other information being provided for the examiner's consideration follows:

[insert other information]

- 6. In accordance with 37 C.F.R. 1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in §1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant reserves the right to prove that the date of publication is in fact different.
- 7. The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C. Attorneys for Applicant

By:

Iver P. Cooper Reg. No. 28,005

624 Ninth Street, N.W. Washington, D.C. 20001 Telephone: (202)628-5197 Facsimile: (202)737-3528

IPC:ses

G:\ipc\g-i\hoib\BERG3\pto\IDSIPC.doc

Mee'd PCTLETO 16 DEC 2005 T SHEET

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE **ATTY DOCKET NO: BERG3** SERIAL NO: 10/532,341 PATENT AND TRADEMARK OFFICE APPLICANT: Kurt Frimann BERG LIST DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary) FILING DATE: September 19, 2003 **GROUP:** U.S. PATENT DOCUMENTS (include at least patentee, patent number and issue date) **EXAMINER** SUB-FILING DATE **DOCUMENT NUMBER** DATE **PATENTEE CLASS** INITIAL **CLASS** IF APPROP. 8 2 AA 6 2 8 4 6 5 AB 5 AC 5 6 9 6 3 1 3 ΑD 6 5 9 2 8 9 6 ΑE 6 5 9 5 4 3 ΑF 4 ō 0 6 2 6 9 4 8 6 AG 2 6 1 АН 0 6 3 3 8 3 6 FOREIGN PATENT DOCUMENTS (include at least document number, publication date and country) **DOCUMENT NUMBER** DATE **COUNTRY** --**CLASS** SUB-**TRANSLATION CLASS** YES/NO ΑI 03 0 3 2 8 02-20-2003 wo 02 02-07-2002 wo AJ 0 9 6 9 9 wo 02 0 0 8 0 2 01-24-2002 ΑK 5 01 9 5 9 0 0 12-20-2001 wo AL WO 01 0 01-18-2001 AM 3 6 8 1 00 3 0 4 4 06-29-200 wo AN AO 85 ō 2 01-17-1985 wo 0 1 1 wo AP 01 4 5 07-12-2001 9 2 8 EP ΔQ 08 6 1 8 07-09-2003 AR 80 0 9 4 8 8 08-22-1996 EΡ AS 10 5 4 01-31-2001 EP 07 6 0 05-15-1996 EΡ AT 1 1 5 ΑU 02 8 8 0 7 10-26-1988 FP ΑV 20 5 9 1 3 02-28-1990 JP 5 ΑW 36 3 0 0 6 12-18-2002 JΡ ΑX 29 4 4 1 10-08-2002 JP 8 07-13-2000 ΑY 12 0 8 3 6 CN OTHER DOCUMENTS (include author, title, name of publication, volume, pages & date of publication) **EXAMINER DATE CONSIDERED** EXAMINER: Initial if reference considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF C	OMMERCE ATTY	DOCKET NO: BERG3	SERIAL NO: 10/532,341		
LIST DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)		CANT: Kurt Frimann BERG			
	FILING	G DATE: September 19, 2003	GROUP:		
OTHER DOCUMENTS (include author, title, n	name of publication, vo	olume, pages and date of publication)			
AZ Eccles, R., "Menthol and Related Cooling Compounds" 1994, J.Pharm. Pharmacol., 46, (Review): 618-630					
	Eccles, R., et al, "The effects of oral administration of ()-methol on nasal resistance to airflow and nasal sensation of airflow in subjects suffering from nasal congestion associated with the common cold"1990, J. Pharm Pharmacol., 42, (9):				
BB Eccles, R., et al, "The effe					
BC Duband et al., "Composition					
BD Ahlgrimm, 1956, "Beitrage					
			-		
EXAMINER		DATE CONSIDERED			
EXAMINER: Initial if reference considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					